• PHC8 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT IN THE UK AND SPAIN

    Nov 1, 2008, 00:00

  • PCV58 COSTS OF CORONARY ARTERY DISEASE (CAD) IN POLAND

    Nov 1, 2008, 00:00

  • PSS1 RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PSS52 SCORING AND PSYCHOMETRIC PROPERTIES OF THE EYE-DROP SATISFACTION QUESTIONNAIRE (EDSQ)

    Nov 1, 2008, 00:00

  • PCN105 MEDICARE PART DS MARKET IMPACT ON UTILIZATION, AVERAGE RETAIL PRICE AND OUT-OF-POCKET SPENDING FOR ORAL CHEMOTHERAPEUTICS AND A COMPARATIVE MARKET BASKET OF DRUGS

    Nov 1, 2008, 00:00

  • PCN48 COST-MINIMIZATION ANALYSIS OF XELOXVERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL

    Nov 1, 2008, 00:00

  • PMC46 SHOULDWE BE CONSIDERING COMPONENTS OF SOCIAL COGNITION MODELS TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSION MEDICATION?

    Nov 1, 2008, 00:00

  • PG122 ASSESSING THE PATIENT-REPORTED IMPACT OF USING BOWEL CLEANSING PREPARATIONS

    Nov 1, 2008, 00:00

  • PSS50 DEVELOPMENT OF AN INSTRUMENT FOR ASSESSING HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA

    Nov 1, 2008, 00:00

  • PMH28 THE ECONOMICS OF SCHIZOPHRENIA IN GERMANY AND THE POTENTIAL OF LONG ACTING SECOND GENERATION DEPOT TREATMENT

    Nov 1, 2008, 00:00

  • PMS64 DIFFERENCES IN QUALITY OF LIFE ACCORDING TO THE REPLACED JOINT

    Nov 1, 2008, 00:00

  • PIN24 ECONOMIC AND CLINICAL IMPACT OF IMPLEMENTATION OF AN ACELLULAR PERTUSSIS VACCINE IN CANADA

    Nov 1, 2008, 00:00

  • PCASE2 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT- A CASE STUDY OF CETUXIMAB AT A MAJOR ACADEMIC CANCER CENTER

    Nov 1, 2008, 00:00

  • OR1 EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS

    Nov 1, 2008, 00:00

  • PCV100 METFORMIN FOR THE TREATMENT OF METABOLIC DISTURBANCES AND CARDIOVASCULAR RISK FACTORS INWOMEN WITH POLYCYSTIC OVARY SYNDROME- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2008, 00:00

  • PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION- IMPACT ON COST AND COST-EFFECTIVENESS

    Nov 1, 2008, 00:00

  • PSS26 PHARMACOECONOMIC EVALUATION OF RANIBIZUMAB IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN AUSTRIA

    Nov 1, 2008, 00:00

  • PSY40 BURDEN OF FIBROMYALGIA TO THE UK NATIONAL HEALTH SERVICE (NHS)

    Nov 1, 2008, 00:00

  • PCN24 PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA-A COST-EFFECTIVENESS STUDY FOR SCOTLAND

    Nov 1, 2008, 00:00

  • PMC30 THE IMPACT OF INITIAL DISEASE SEVERITY- AN APPLICATION TO EXISTING HEALTH ECONOMICS MODELS

    Nov 1, 2008, 00:00

  • PMH55 A COMPARISON OF PERSISTENCE AND HEALTH CARE COSTS RELATED TO DIFFERENT TREATMENT STRATEGIES AFTER INITIAL ESCITALOPRAM 10MG IN MAJOR DEPRESSIVE DISORDER

    Nov 1, 2008, 00:00

  • PSS20 SENSITIVE SKINS IN ITALY- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PG127 PSYCHOMETRIC VALIDATION OF TRANSLATION TO SPANISH OF THE REFLUX DISEASE QUESTIONNAIRE (RDQ) AND GASTROINTESTINAL IMPACT SCALE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    Nov 1, 2008, 00:00

  • PMS42 COST-UTILITY EVALUATION OF THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS WITH IN SAPONIFICATES OF AVOCADO AND SOY (PIASCLEDINE )

    Nov 1, 2008, 00:00

  • PSY33 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLOODTRANSFUSION DURING INPATIENT HOSPITALIZATION- AN ANALYSIS OF THE 2004 HEALTH CARE COST AND UTILIZATION PROJECT NATIONWIDEINPATIENT SAMPLE DATABASE

    Nov 1, 2008, 00:00

  • PIH23 MEDICATION COSTS IN ELDERLY PATIENTS

    Nov 1, 2008, 00:00

  • PCV33 COST OF OUTPATIENT HYPERTENSION PHARMACOTHERAPY-COMPARATIVE STUDY BETWEEN BULGARIA AND SERBIA

    Nov 1, 2008, 00:00

  • PMH10 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE- A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS IN SCHIZOPHRENIA

    Nov 1, 2008, 00:00

  • PSY48 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA- PATIENT-REPORTED DATA. INTERMEDIATE RESULTS. PART 2

    Nov 1, 2008, 00:00

  • PHC11 THE BURDEN OF ADHESIOLYSIS DURING LAPAROSCOPIC GYNECOLOGICAL SURGERY

    Nov 1, 2008, 00:00

  • PSS42 PSORIASIS AND THERMAL THERAPY- EVALUATION OF MEDICAL SERVICE

    Nov 1, 2008, 00:00

  • MO1 ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS

    Nov 1, 2008, 00:00

  • PG12 UNCONTROLLED GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)- FINDINGS FROM A UK MULTICENTRE, CROSS-SECTIONAL STUDY

    Nov 1, 2008, 00:00

  • PMH50 THE ROLE OF PRE-TREATMENT EXPECTANCY ON THE OUTCOME OF PRIMARY CARE TREATMENTS FOR DEPRESSION

    Nov 1, 2008, 00:00

  • PSY49 PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH NEUROPATHIC PAIN- A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL ...

    Nov 1, 2008, 00:00

  • PIH22 PRICE-ELASTICITY OF DEMAND FOR INFERTILITY SERVICES IN GERMANY

    Nov 1, 2008, 00:00

  • PSS13 HAIR LOSS- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCN12 BUDGETARY IMPACT OF XELOX IN COLORECTAL CANCER IN ITALY

    Nov 1, 2008, 00:00

  • PHC2 IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL SURGERY ON HOSPITAL BUDGET

    Nov 1, 2008, 00:00

  • PCN43 MODELING THE COST-EFFECTIVENESS OF PROSTATE CANCERTREATMENT WITH PARTICLE THERAPY

    Nov 1, 2008, 00:00

  • PSY52 QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES. INTERMEDIATE RESULTS

    Nov 1, 2008, 00:00

  • PCV22 TOLERABILITY OF ROSUVASTATIN 40 MG COMPARED TO 20 MG IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA- EVIDENCE FROM RANDOMISED CONTROLLED TRIALS

    Nov 1, 2008, 00:00

  • PCASE4 BRIDGING THE GAP OF EVIDENCE AND COSTEFFECTIVENESS- THE PRAGMATIC APPROACH USING ECONOMIC MODELLING TO ASSESS THE COSTEFFECTIVENESS FOR ASSISTIVE TECHNOLOGIES (AT) IN THE UK-BOTH PRE-AND POSTMARKETED

    Nov 1, 2008, 00:00

  • OR3 ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL COSTS- DEVELOPMENT AND APPLICATION OF A TOOLKIT

    Nov 1, 2008, 00:00

  • PIH1 CHANGES IN PELVIC FLOOR MUSCLE STRENGTH, ITS DURATION AND ITS RELAXATION ABILITY DURING PREGNANCY

    Nov 1, 2008, 00:00

  • PMC15 IN OR OUT? EMPIRICAL EVIDENCE ON INCOME LOSSES IN HEALTH STATE VALUATIONS AND IMPLICATIONS FOR ECONOMIC EVALUATIONS

    Nov 1, 2008, 00:00

  • PND27 UTILIZATION PATTERNS OF ANTIEPILEPTIC DRUGS- AN ITALIAN PRESCRIPTION DATABASE ANALYSIS

    Nov 1, 2008, 00:00

  • OR2 INCORPORATING DIFFUSION OF NEW MEDICINES IN A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PIN30 COST-EFFECTIVENESS ANALYSIS OF DROTRECOGIN ALFA (ACTIVATED; DAA) AS A TREATMENT FOR SEVERE SEPSIS WITH MULTIPLE ORGAN FAILURE (MOF) IN POLAND

    Nov 1, 2008, 00:00

  • HT1 A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES

    Nov 1, 2008, 00:00

  • PCV75 THE IMPACT OF POSTPRANDIAL PEAKS ON CARDIOVASCULAR COMPLICATIONS BEYONDTHE HBA1C LEVEL-A HEALTH ECONOMIC ASSESSMENT

    Nov 1, 2008, 00:00

  • PIN35 HEALTH ECONOMIC ASSESSMENT OF A PRE-PANDEMIC INFLUENZA VACCINE FOR GERMANY

    Nov 1, 2008, 00:00

  • PMS49 HEALTH-RELATED QUALITY OF LIFE (HRQL) OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) PATIENTS IN GREECE- PRELIMINARY RESULTS FROM THE HEOR STUDY

    Nov 1, 2008, 00:00

  • PMC9 DISCOUNTING COSTS AND BENEFITS OF HEALTH CARE PROGRAMMES- PROBLEMS OF THE SOCIAL TIME PREFERENCE APPROACH

    Nov 1, 2008, 00:00

  • PMH53 PREDICTIVE FACTORS OF RECURRENCE AND BIPOLAR DISORDER MANAGEMENT IN SPAIN- A PROSPECTIVE COHORT STUDY BASELINE ASSESSMENT

    Nov 1, 2008, 00:00

  • MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS- THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMS56 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ)- VALIDATION OF A TOOL TO AID DIAGNOSIS

    Nov 1, 2008, 00:00

  • PHP33 INFLUENCE OF MORBIDITY ON THE USE OF RESOURCES IN PRIMARY CARE- RETROSPECTIVE APPLICATION OF ACG AT A SPANISH INTERREGIONAL LEVEL

    Nov 1, 2008, 00:00

  • PMC10 PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2008, 00:00

  • PMC45 WHAT PROPORTION OF DISEASES ARE QALYS AN IRRELEVANT MEASURE FOR?

    Nov 1, 2008, 00:00

  • PCN31 ECONOMIC EVALUATION OF CLODRONATE AND ZOLENDRONATE IN PATIENTS DIAGNOSED WITH METASTATIC BONE DISEASE FROM THE PERSPECTIVE OF THIRD PARTY PAYORS IN BRAZIL

    Nov 1, 2008, 00:00

  • PG121 REDUCTION OF WORK PRODUCTIVITY ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD) AND RELATED COSTS

    Nov 1, 2008, 00:00

  • PCN75 AN UPDATED GEOGRAPHIC SUBPOPULATION ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) ENROLLED IN A PHASE III TRIAL OF SUNITINIB VERSUS INTERFERON-ALFA

    Nov 1, 2008, 00:00

  • DB4 COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PMH39 RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND PATIENTS REPORTED OUTCOMES IN SCHIZOPHRENIA- THE CONTRIBUTION OF THE EQ-5D

    Nov 1, 2008, 00:00

  • HP3 TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US CLAIMS DATABASE

    Nov 1, 2008, 00:00

  • PCN109 DEALING WITH QUALITY OF LIFE MISSING DATA IN A SINGLE ARM STUDY. COMPARISON OF MULTIPLE IMPUTATION METHODS

    Nov 1, 2008, 00:00

  • PND17 ONE-YEAR EXPENSES FOR THE PHARMACOLOGICAL MANAGEMENT OF EPILEPSY WITHIN OUTPATIENT SETTING OF MONTENEGRO- RATIONAL OR NOT?

    Nov 1, 2008, 00:00

  • PIN51 EVALUATION OF SEPSIS MANAGEMENT AND OUTCOMES AT A LARGE INNER-CITY ACADEMIC MEDICAL CENTER IN THE SURVIVING SEPSIS CAMPAIGN ERA

    Nov 1, 2008, 00:00

  • PMH45 A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY

    Nov 1, 2008, 00:00

  • PDB30 INSTIGATE STUDY (INSULIN TITRATION; GAINING AN UNDERSTANDING OF THE BURDEN OF TYPE 2 DIABETES IN EUROPE)- HEALTH CARE RESOURCE UTILIZATION AND COSTS WITHIN THE FIRST 6 MONTHS OF INSULIN THERAPY-FRENCH DATA

    Nov 1, 2008, 00:00

  • PMS33 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN SPAIN

    Nov 1, 2008, 00:00

  • PMC13 ESTIMATING COST-OF-ILLNESS USING GENERALIZED LINEAR MODELS- AN ALTERNATIVE TO THE SMEARING APPROACH

    Nov 1, 2008, 00:00

  • PCV74 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUSTHROMBOEMBOLISM IN PATIENTS UNDERGOINGTOTAL HIP ORTOTAL KNEE REPLACEMENT SURGERY

    Nov 1, 2008, 00:00

  • PSY55 PAIN MANAGEMENT IN THAILAND- IMPLICATION FOR BETTER PATIENT EDUCATION

    Nov 1, 2008, 00:00

  • PHP20 THE EFFECT OF THE INTRODUCTION OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITALWARDS IN HUNGARY

    Nov 1, 2008, 00:00

  • PDB13 REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND- A BUDGT IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PMC24 SELF-ASSESSED HEALTH STATUS IN POLAND- EQ-5D FINDINGS FROM POLISH VALUATION STUDY

    Nov 1, 2008, 00:00

  • PSS12 SENSITIVE SKINS IN PORTUGAL- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCV30 COST-EFFECTIVENESS ANALYSIS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) FOR ABDOMINAL AORTIC ANEURYSM (AAA) IN SPAIN

    Nov 1, 2008, 00:00

  • IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM

    Nov 1, 2008, 00:00

  • PDB7 LONGTERM HEALTH OUTCOMES IN NEWLY DIAGNOSED TREATMENT NA VE TYPE 2 DIABETES PATIENTS INITIATED WITH BIPHASIC INSULIN ASPART IN CHINA- DATA FROM THE IMPROVE STUDY

    Nov 1, 2008, 00:00

  • PDB53 VALIDATION OF THE HUMAN GROWTH HORMONE PREFERENCE AND SATISFACTION QUESTIONNAIRE (HGH-PSQ)

    Nov 1, 2008, 00:00

  • PCN4 EFFICACY OF OPIOIDS IN THE TREATMENT OF BREAKTHROUGH CANCER PAIN- A BAYESIAN MIXED TREATMENT COMPARISON

    Nov 1, 2008, 00:00

  • PCN78 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN TREATMENT WITH PLACITAXEL WITH/WITHOUT BEVACIZUMAB, RELATED WITH TREATMENT RESPONSE (REMISSION AND PROGRESSION)

    Nov 1, 2008, 00:00

  • PCN111 A STRUCTURED REVIEW OF STUDIES ON HEALTH-RELATED QUALITY OF LIFE IN KIDNEY CANCER, HEPATOCELLULAR CARCINOMA AND LEUKEMIA

    Nov 1, 2008, 00:00

  • PSY61 INCREMENTAL SAVINGS ASSOCIATED WITH A DECREASE IN ANTIDEPRESSANT MEDICATIONS FOLLOWING BARIATRIC SURGERY IN WESTERN NEWYORK

    Nov 1, 2008, 00:00

  • PSS33 THE COST OF UVEITIS TREATMENT IN FRANCE- A ONE-YEAR RETROSPECTIVE ANALYSIS

    Nov 1, 2008, 00:00

  • PUK17 ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER

    Nov 1, 2008, 00:00

  • PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST- ODDS SOLUTION TO RELATIVE RISK FALLACIES

    Nov 1, 2008, 00:00

  • PCV76 THE KOREAN INDIVIDUAL-MICROSIMULATION MODEL FOR CARDIOVASCULAR HEALTH INTERVENTIONS (KIMCHI)

    Nov 1, 2008, 00:00

  • PRS2 RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN

    Nov 1, 2008, 00:00

  • PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PRS7 THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN SPAIN- AN ECOMIC MODELTO ESTIMATE BUDGET IMPACT CONSEQUENCES OF INTRODUCING BECLOMETHASONE/FORMOTEROL

    Nov 1, 2008, 00:00

  • PHP47 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTH SERVICE UTILIZATION AMONG PRIMARY CARE PATIENTS

    Nov 1, 2008, 00:00

  • PND11 EPILEPSY COST OF ILLNESS IN THE U.S. PRIVATELY INSURED

    Nov 1, 2008, 00:00

  • PSY8 BUDGET IMPACT ANALYSIS OF DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH BETATHALASSAEMIA IN VENETO REGION, ITALY

    Nov 1, 2008, 00:00

  • PIN48 VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2008, 00:00

  • PCV46 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION- A SPANISH MODEL BASED ON THE CLARITY AND COMMITTRIALS

    Nov 1, 2008, 00:00

  • PCN18 AN EVALUATION OF THE COST SAVINGS GENERATED WITH THE USE OF AN INTRA-OPERATIVE ASSAY FOR THE DETECTION OF METASTASES IN THE SENTINEL LYMPH NODES OF PATIENTS WITH BREAST CANCER

    Nov 1, 2008, 00:00

  • MH4 HEALTH SERVICE EXPENDITURES FOR CHILDREN AND ADOLESCENTS WITH AND WITHOUT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY-IMPACT OF COEXISTING CONDITIONS

    Nov 1, 2008, 00:00

  • PDB10 COMPREHENSIVE LIPID PROFILE AMONGTYPE 2 DIABETES MELLITUS (T2DM) POPULATION IN SPAIN. RECAP-DM SPANISH COHORT STUDY

    Nov 1, 2008, 00:00

  • EE1 DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH CARE DECISIONS- DOES HIERARCHICAL INFORMATION INTEGRATION OFFER A SOLUTION?

    Nov 1, 2008, 00:00

  • PDB51 UNDERSTANDING AND ASSESSING THE IMPACT OF DIABETES TREATMENT ACROSS MEDICATION DELIVERY SYSTEMS

    Nov 1, 2008, 00:00

  • PCV5 A REALWORLD COMPARISON OF COMBINED LIPID TARGET ATTAINMENT BETWEEN COMBINATION NIACIN EXTENDED-RELEASEEZETIMIBE

    Nov 1, 2008, 00:00

  • PIN49 INTERNATIONAL DEVELOPEMENT OF A NEW HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO HIV/AIDS-PROQOL HIV STUDY

    Nov 1, 2008, 00:00

  • PDB18 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR SITAGLIPTIN

    Nov 1, 2008, 00:00

  • PHP23 CHARACTERISTICS OF UTILIZATION OF PRIMARY CARE OF GENERAL PRACTITIONERS IN COUNTY BARANYA IN HUNGARY

    Nov 1, 2008, 00:00

  • PSS5 IMPACT OF COMPLIANCE ON INTRA-OCULAR PRESSURE (IOP) CONTROL IN GLAUCOMA PATIENTS

    Nov 1, 2008, 00:00

  • PCN30 COST-EFFECTIVENESS OF APREPITANT IN PATINENTS RECEIVING ANTIEMETIC PROPHYLAXIS FOR HIGHLY EMETOGENIC CHEMOTHERAPY IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN72 THE IMPACT OF INITIAL TREATMENT CHOICE AND DISEASE PROGRESSION ON THE ECONOMIC BURDEN OF PATIENTS AND THEIR CAREGIVERS-A LONGITUDINAL STUDY OF STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2008, 00:00

  • PND7 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMH8 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE IN THE TREATMENT OF ACUTE BIPOLAR DISORDER- AN ADJUSTED INDIRECT COMPARISON

    Nov 1, 2008, 00:00

  • PMH48 TELEPHONE HOTLINE AS AN ADJUNCT TO CONTINUING CARE FOR ADOLESCENTS TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER

    Nov 1, 2008, 00:00

  • PRS33 FACTORS AFFECTING QUALITY OF LIFE OF ASTHMATIC AND COPD PATIENTS

    Nov 1, 2008, 00:00

  • PMS14 NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY- A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PMH9 TOLERABILITY OF A TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER- A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2008, 00:00

  • PMH21 COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA- 12 MONTH DATA FROM CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PCN96 ASSOCIATION BETWEEN RESPONDENT- AND PRACTICE-RELATED CHARACTERISTICS AND RADIATION ONCOLOGY STAFF-REPORTED BURDEN ON MUCOSITIS MANAGEMENT FOR HEAD AND NECK CANCER (HNC) PATIENTS

    Nov 1, 2008, 00:00

  • PMH11 DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE- THE BUDGET IMPACT OF ILLEGAL DRUGS

    Nov 1, 2008, 00:00

  • HP1 ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007

    Nov 1, 2008, 00:00

  • PIN40 MANAGEMENT AND COST ASSOCIATED WITH NON-PERMANENT CATHETER-RELATED BACTERAEMIA CAUSED BY MICROORGANISMS GRAM-POSITIVES IN SPANISH HOSPITALS SETTINGS

    Nov 1, 2008, 00:00

  • PND22 ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

    Nov 1, 2008, 00:00

  • PCN28 COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

    Nov 1, 2008, 00:00

  • PMS12 THE ROLE OF DIFFERENT CO-MORBIDITIES IN THE EVALUATION OF CORRELATION BETWEEN CERTAIN RISK FACTORS AND THE ONE YEAR MORTALITY FOLLOWING FEMORAL NECK FRACTURE

    Nov 1, 2008, 00:00

  • EE4 CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS

    Nov 1, 2008, 00:00

  • PMH36 WHAT DO PATIENTS WITH SCHIZOPHRENIAWANT OUT OF THEIR MEDICATION? IDENTIFYING PATIENT REPORTED 'PROCESSES' IN MENTAL HEALTH

    Nov 1, 2008, 00:00

  • PSS31 ACUTE OTITIS MEDIA- A MAJOR SOURCE OF PRODUCTIVITY LOSS

    Nov 1, 2008, 00:00

  • PRS35 CHALLENGING ASTHMA MANAGEMENT WITH THE USE OF LABA/ICS COMBINATION VIA ATURBUHALER DEVICE, BOTH FOR MAINTENANCE AS WELL AS RELIEF, AND IT WELL-BEING IN GREECE

    Nov 1, 2008, 00:00

  • PCV101 PROSPECTIVE STUDY TO EVALUATE THE IMPACT OF A DISEASE EDUCATION PROGRAM OF CARDIOVASCULAR RISK CONTROL IN HYPERTENSION

    Nov 1, 2008, 00:00

  • PG120 ASSESSING THE COST AND EFFECTIVENESS OF TERLIPRESSIN COMPARED WITH SOMATOSTATIN FOR THE TREATMENT OF BLEEDING OESOPHAGEAL VARICES IN SPAIN

    Nov 1, 2008, 00:00

  • PMC2 HASTHE QUALITY OF RANDOMISED CONTROLLED TRIALS INCREASED WITH TIME- AN ANALYSIS OF DATA FROM 5 SYSTEMATIC REVIEWS?

    Nov 1, 2008, 00:00

  • EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS- A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION

    Nov 1, 2008, 00:00

  • PMS6 PREVALENCE OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PCV99 A CROSS-NATIONAL COMPARISON ON PRICES OF PHARMACEUTICAL PRODUCT

    Nov 1, 2008, 00:00

  • PHP21 THE EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN107 NEW OPPORTUNITIES FOR DRUG OUTCOMES RESEARCH IN CANCER PATIENTS- VALIDATION OF THE LINKAGE OF THE EINDHOVEN CANCER REGISTRY AND THE PHARMO RECORD LINKAGE SYSTEM

    Nov 1, 2008, 00:00

  • PSS57 RETROSPECTIVE CHART REVIEW TO ASSESS IMPLEMENTATION OF NICE GUIDANCE ON THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS

    Nov 1, 2008, 00:00

  • Author Index

    Nov 1, 2008, 00:00

  • PMH18 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN LONG-TERM TREATMENT OF SCHIZOPHRENIA IN TURKEY

    Nov 1, 2008, 00:00

  • PDB52 A SELF-MANAGEMENT PROFILE FOR PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2008, 00:00

  • PDB28 DIABETES MELLITUS BURDEN AND RELATIONSHIP WIHTHE DEGREE OF PATIENTxS GLYCEMIC CONTROL

    Nov 1, 2008, 00:00

  • MH8 DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE- REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)

    Nov 1, 2008, 00:00

  • PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE

    Nov 1, 2008, 00:00

  • PMS39 COST-UTILITY OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INSUFFICIENT RESPONSE OR INTOLERANCE TO ANTI-TNF THERAPY IN ITALY- A PROBABILISTIC SENSITIVITY ANALYSIS

    Nov 1, 2008, 00:00

  • MS2 LINGUISTIC VALIDATION OF SIX QUALITY OF LIFE QUESTIONNAIRES FOR FIBROMYALGIA PATIENTS IN TWELVE LANGUAGES

    Nov 1, 2008, 00:00

  • PMH1 PREVALENCE OF TIC DISORDERS AND COEXISTENCE WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN A GERMAN COMMUNITY SAMPLE

    Nov 1, 2008, 00:00

  • PHP53 EXPANDINGTHE PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI)- MEASURES GROUPS AND REGISTRY-BASED REPORTING

    Nov 1, 2008, 00:00

  • PMH41 SAD BLUE DEPRESSED DAYS, HEALTH-RELATED QUALITY OF LIFE, AND HEALTH BEHAVIORS AMONGWOMEN IN A UNIVERSITY COMMUNITY

    Nov 1, 2008, 00:00

  • PSY15 ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME

    Nov 1, 2008, 00:00

  • PCN11 BUDGET IMPACT ANALYSIS OF DIFFERENT TREATMENT PROTOCOLS FORTRASTUZUMAB

    Nov 1, 2008, 00:00

  • PCV98 MODELLING THE EFFECT OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) ON CAPACITY AND PRODUCTIVITY OF CORONARY DIAGNOSTIC FACILITIES IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PSS6 EFFECTIVENESS OF MOXIFLOXACIN IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS IN ADULTS

    Nov 1, 2008, 00:00

  • PMS23 INITIAL COMBINATION THERAPY WITH INFLIXIMAB VERSUS SEQUENTIAL DMARD MONOTHERAPY- A COST-EFFECTIVENESS MODEL BASED ON THE BEST STUDY

    Nov 1, 2008, 00:00

  • PUK22 FACTORS ASSOCIATED WITH PERCEIVED SATISFACTION IN HEMODYALISIS PATIENTS

    Nov 1, 2008, 00:00

  • PHP38 COST-EFFECTIVENESS OF PREVENTION- OPPORTUNITIES FOR PUBLIC HEALTH POLICY IN THE NETHERLANDS?

    Nov 1, 2008, 00:00

  • PCN82 TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EQ-5D

    Nov 1, 2008, 00:00

  • PCN34 PHARMAECONOMIC EVALUATION OF THE USE OF ERLOTINIB IN NON-SMALL CELLS LUNG CANCER (NSCLC) WITH FAILURE TO PREVIOUS CHEMOTHERAPY

    Nov 1, 2008, 00:00

  • PCV29 ESTIMATING THE BUDGET IMPACT OF DABIGATRAN ETEXILATE IN THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWINGTOTAL HIP OR KNEE REPLACEMENT SURGERY- AN INTERACTIVE MODEL FOR LOCAL HEALTH ECONOMIES IN THE UK

    Nov 1, 2008, 00:00

  • PMH24 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ADULT DEPRESSED MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PMC55 THE C-STATISTIC AND THE EFFICIENCY OF THE PROPENSITY SCORES MODEL- EVIDENCE FROM SIMULATED DATA

    Nov 1, 2008, 00:00

  • PUK9 COST OF OVERACTIVE BLADDER IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PHP18 COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND THERAPEUTIC DEVICES OR DRUGS

    Nov 1, 2008, 00:00

  • CV1 WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS?

    Nov 1, 2008, 00:00

  • PMC29 PATIENT REPORTED OUTCOMES RESEARCH IN A REAL TIME PRACTICE NETWORK

    Nov 1, 2008, 00:00

  • PND9 WITHIN-TRIAL COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE COMPARED TO STANDARD-OF-CARE IN THE SCHIZOPHRENIA TRIAL OF ARIPIPRAZOLE (STAR)

    Nov 1, 2008, 00:00

  • PIH14 COSTS AND OUTCOMES ASSOCIATED WITH IN VITRO FERTILISATION (IVF) OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) USING RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH)

    Nov 1, 2008, 00:00

  • PND24 CANTHE CHQ-PF50 BE USED TO MONITOR CHANGES IN BEHAVIORAL AND EMOTIONAL FUNCTIONING IN CHILDREN TREATED FOR EPILEPSY?

    Nov 1, 2008, 00:00

  • PCV13 ATTAINMENT OF MULTIPLE RECOMMENDED LIPID LEVELS FOLLOWING LIPID MODIFYING TREATMENT IN HIGH RISK PATIENTS. PRIMULA STUDY, SPAIN

    Nov 1, 2008, 00:00

  • PG135 PATIENT PREFERENCES FOR CROHNS DISEASE FLARE-UP THERAPY- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PMS40 COST-EFFECTIVENESS ANALYSIS OF ANNUAL DOSE OF ZOLEDRONIC ACID VERSUS ORALLY ADMINISTERED BISPHOSPHONATES IN PREVENTION OF OSTEOPOROTIC FRACTURES IN CZECH POST-MENOPAUSALWOMEN

    Nov 1, 2008, 00:00

  • PMC31 VALUING EQ-5D WITH TIME TRADE-OFF FOR THE POLISH POPULATION

    Nov 1, 2008, 00:00

  • PG18 A COST-EFFECTIVENESS EVALUATION-RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE

    Nov 1, 2008, 00:00

  • PG123 QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS WITH ULCERATIVE COLITIS IN REMISSION VS. MILD/MODERATE AND SEVERE RELAPSE- FINDINGS FROM THE PODIUM STUDY

    Nov 1, 2008, 00:00

  • PRS40 DECISION-MAKING IN HEALTH CARE USING COST-EFFECTIVENESS EVIDENCE-SMOKING CESSATION COMPARED TO TREATMENT OF SMOKING-RELATED DISEASES

    Nov 1, 2008, 00:00

  • PG114 A HYPOTHETICAL ROAD MAPTO REDUCE ACID RELATED DISEASES COSTS MANAGEMENT

    Nov 1, 2008, 00:00

  • PSS29 SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY

    Nov 1, 2008, 00:00

  • PRS28 HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS OF A SURVEY IN 5 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PHP15 DETERMINANTS OF PHARMACEUTICAL CONSUMPTION IN A GENERAL POPULATION

    Nov 1, 2008, 00:00

  • PMC23 WHAT IS POLITICIANS WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENTVALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES

    Nov 1, 2008, 00:00

  • PCV50 COST-EFFECTIVENESS OF RULING OUT DEEPVENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL

    Nov 1, 2008, 00:00

  • PCV73 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR- ACUTE INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN EMERGENCY SETTING

    Nov 1, 2008, 00:00

  • PMH29 HEALTH CARE RESOURCE UTILIZATION AND COSTS OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PSY51 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS

    Nov 1, 2008, 00:00

  • PRS12 COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART VERSUS FIXED COMBINATION TREATMENTS IN FINLAND

    Nov 1, 2008, 00:00

  • PIH2 ONE DAY NATIONAL SURVEY ON PREVALENCE OF MALE SEXUAL DYSFUNCTION, AMONG MEN CONSULTING UROLOGISTS

    Nov 1, 2008, 00:00

  • PCN5 TREATMENT EFFECT OF RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE (R-FC) VERSUS FC IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN AN OBSERVATIONAL SETTING- AN INVESTIGATION OF PROGNOSTIC FACTORS AND LIFETIME HEALTH OUTCOMES

    Nov 1, 2008, 00:00

  • PSY58 RETROSPECTIVE ANALYSIS OF FACTORVIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER RECOMBINANT B DOMAIN-DELETED OR FULL-LENGTH FACTOR VIII

    Nov 1, 2008, 00:00

  • PSS59 IMPACT OF HEALTH CARE REGULATION ON PROSTAGLANDIN ANALOGUE PRESCRIBING IN 5 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PIN8 PATIENT FLOW PATHWAY FOR PATIENTS ADMITTED TO CRITICAL CARE UNITS WITH A SEVERE BACTERIAL INFECTION IN ENGLAND

    Nov 1, 2008, 00:00

  • PIN13 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR TREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN ITALY

    Nov 1, 2008, 00:00

  • PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE 'ANTI-AGING-MEDICINE' FIELD- RESULTS FROM A SYSTEMATIC HORIZON SCANNING

    Nov 1, 2008, 00:00

  • PG111 A COST-EFFICACY ANALYSIS MODEL FOR PHYSICIAN ADMINISTERED ANTI-TUMOR NECROSIS FACTOR AGENTS IN CROHNS DISEASE

    Nov 1, 2008, 00:00

  • PHP2 CONSUMERS PERCEPTIONS OF DRUG EFFECTIVENESS AND PRICES IN GREECE

    Nov 1, 2008, 00:00

  • PIH17 TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE MENOPAUSE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE

    Nov 1, 2008, 00:00

  • PSY16 THE ECONOMIC IMPACT OF DIFFERENT STRATEGIES OF MANAGING RARE DISEASES WITH HIGH TREATMENT COSTS- THE CASE OF USING ACTIVATED RECOMBINANT FACTORVII IN SEVERE BLEEDS IN ACQUIRED HAEMOPHILIA PATIENTS

    Nov 1, 2008, 00:00

  • PCV123 THE CARDIOVASCULAR PREVENTION MODEL (CPM), A GENERICALLY APPLICABLE MODEL FOR UNDERTAKING COST-EFFECTIVENESS ANALYSES OF PREVENTIVE INTERVENTIONS

    Nov 1, 2008, 00:00

  • PDB15 COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND

    Nov 1, 2008, 00:00

  • PCV91 IMPACT OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUGS ON QUALITY OF LIFE IN PATIENTS WITH A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PCV15 CORONS STUDY- EXAMPLE OF STATINS IMPACT ON ALL CAUSE MORTALITY IN THE ELDERLY

    Nov 1, 2008, 00:00

  • PRS39 GIVING-UP SMOKING- PREDICTIVE FACTORS OF SMOKING CESSATION AND ATTEMPTS TO STOP IN A FRENCH COHORT

    Nov 1, 2008, 00:00

  • PCV121 LIPID MANAGEMENT OF HIGH RISK PATIENTS IN THE OUTPATIENT SETTING IN GERMANY- RESULTS OF DYSIS-GERMANY

    Nov 1, 2008, 00:00

  • PG15 A BUDGET IMPACT ANALYSIS FOR DETERMINING THE COSTS OF INCREASED PANTOPRAZOL IV PRESCRIPTION FOR THE MANAGEMENT OF PEPTIC ULCER IN SPAIN

    Nov 1, 2008, 00:00

  • PSY24 MANAGEMENT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM- A COST OF ILLNESS STUDY

    Nov 1, 2008, 00:00

  • QL12 FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA) QUESTIONNAIRE

    Nov 1, 2008, 00:00

  • PIN42 DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSS ASSOCIATED WITH VENOUS LEG ULCER

    Nov 1, 2008, 00:00

  • PUK21 CONTENTVALIDITY OF THE SUBJECTS HEALTH QUESTIONNAIRE, AND INTERNATIONAL CONSULTATION ON INCONTINENCE QUESTIONNAIRE-SHORT FORM IN PATIENTS WITH OAB

    Nov 1, 2008, 00:00

  • PMH31 A GPRD-BASED COMPARISON OF SECOND-LINE ANTIDEPRESSANT THERAPY WITH ESCITALOPRAM AND VENLAFAXINE

    Nov 1, 2008, 00:00

  • PUK10 ECONOMIC IMPACT OF A LOW-PROTEIN DIET AIMING TO DELAY THE HAEMODIALYSIS TREATMENT IN PATIENTS WITH CHRONIC-RENAL-FAILURE

    Nov 1, 2008, 00:00

  • PDB42 COST-UTILITY OF INSULIN GLARGINE COMPARED TO PRE MIX IN TYPE 2 FROM PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2008, 00:00

  • OR4 UTILITIES SHOULD NOT BE MULTIPLIED- EVIDENCE FROM THE PREFERENCE-BASED SCORES IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PSS56 PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA

    Nov 1, 2008, 00:00

  • PCV77 COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK

    Nov 1, 2008, 00:00

  • PDB8 BURDEN OF DIABETES AND ASSOCIATED TREATMENT PATTERNS IN EUROPE- A COMPARISON OF SIX COUNTRIES

    Nov 1, 2008, 00:00

  • PHC13 CHANGINGTHE SURGICALWOUND CLOSURE MANAGEMENT PATHWAY- TIME AND SUPPLIES WITH PRINEO VS. STANDARD OF CARE FOR ABDOMINOPLASTY SURGERY IN GERMANY

    Nov 1, 2008, 00:00

  • PIN21 ECONOMICAL EVALUATION OF ETRAVIRINE IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS BASED ON DUET TRIALS

    Nov 1, 2008, 00:00

  • PMC1 COLLECTING REAL DATA FROM REAL PATIENTS

    Nov 1, 2008, 00:00

  • PSS22 FINAL EVALUATION OF THE PERSISTENCE DEGREE OF PATIENTS IN FIRST-LINE MONOTHERAPY ANTIGLAUCOMATOUS TREATMENT IN SPAIN

    Nov 1, 2008, 00:00

  • PCV113 PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION- WHOARE THE 'UNTREATED PATIENTS' IN HOSPITALS WITH CATH LAB?

    Nov 1, 2008, 00:00

  • PCV49 COST-EFFECTIVENESS OF ATORVASTATIN 80 MGVS GENERIC SIMVASTATIN 20 TO 40 MG IN SECONDARY PREVENTION IN SPAIN

    Nov 1, 2008, 00:00

  • PMS10 PREVALENCE OF FIBROMYALGIA IN SPAIN

    Nov 1, 2008, 00:00

  • PMS38 COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA

    Nov 1, 2008, 00:00

  • PIN6 AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS) AND RIBAVIRIN IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING

    Nov 1, 2008, 00:00

  • CV3 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES

    Nov 1, 2008, 00:00

  • PIN22 COST-EFFECTIVENESS ANALYSIS OF VACCINATION AGAINST ROTAVIRUS WITH RIX4414 IN FRANCE

    Nov 1, 2008, 00:00

  • MO3 COMPARING METHODS OF DATA SYNTHESIS- UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL

    Nov 1, 2008, 00:00

  • MH1 HOW MUCH SHOULDWE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)?

    Nov 1, 2008, 00:00

  • PIN4 A MARKOV MODELTO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY

    Nov 1, 2008, 00:00

  • PSY41 REVIEW OF HOME READINESS INSTRUMENTS TO ASSESS RECOVERY POST-SURGERY

    Nov 1, 2008, 00:00

  • PSY14 COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES III AND IV- TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER ...

    Nov 1, 2008, 00:00

  • EE3 VARIATION IN DIRECT MEDICAL COSTS BY DISEASE SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS CVIRUS

    Nov 1, 2008, 00:00

  • PCV14 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS-GREECE

    Nov 1, 2008, 00:00

  • PMH52 PILOT SURVEY OF ADVERSE EVENT MANAGEMENT ASSOCIATED WITH ANTIPSYCHOTIC USE- THE NEGLECTED DIMENSION IN RESOURCE USE IMPLICATIONS (A UK PERSPECTIVE)

    Nov 1, 2008, 00:00

  • PIH19 THE ASSOCIATION OF BODY MASS INDEX ON HEALTH RELATED QUALITY OF LIFE IN THE GENERAL ADULT POPULATION IN ENGLAND

    Nov 1, 2008, 00:00

  • PMC22 THE IMPACT OF COMORBIDITY BURDEN AND AGE ON PREFERENCE-BASED HRQL IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PDB40 COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE DM1 FROM A PUBLIC PAYER PERSPECTIVE IN POLAND

    Nov 1, 2008, 00:00

  • MD2 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF ENDEVOR DRUG-ELUTING STENT COMPARED TO BARE-METAL STENTS AND CORONARY ARTERY BYPASS GRAFT SURGERY IN SPAIN

    Nov 1, 2008, 00:00

  • PMH19 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA IN NORWAY

    Nov 1, 2008, 00:00

  • PCN76 HEALTH-RELATED QUALITY OF LIFE EVALUATION IN ROMANIAN CANCER PATIENTS

    Nov 1, 2008, 00:00

  • PHC4 COST-EFFECTIVENESS OF HARMONIC SCALPEL USE VERSUS CONVENTIONALTOTAL THYROIDECTOMY

    Nov 1, 2008, 00:00

  • PMH16 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY

    Nov 1, 2008, 00:00

  • PIN31 COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR, TWO NEW HIV TREATMENTS FOR TREATMENT-EXPERIENCED PATIENTS

    Nov 1, 2008, 00:00

  • PMC47 A STUDY OF THE KEY FACTORS INFLUENCING THE PATIENT SATISFACTION IN INPATIENT AND OUTPATIENT SETTINGS

    Nov 1, 2008, 00:00

  • PCV21 EFFECT OF WEATHER CONDITIONS ON THE MORTALITY OF HEART ATTACKS IN HUNGARY

    Nov 1, 2008, 00:00

  • PDB23 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A SWEDISH SETTING

    Nov 1, 2008, 00:00

  • PSS21 ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANY

    Nov 1, 2008, 00:00

  • PHP10 PHARMACY AND HOSPITAL MARKET PERFORMANCE INDICATORS IN FINLAND 1995-2007

    Nov 1, 2008, 00:00

  • PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY- A COSTEFFECTIVENESS ANALYSIS

    Nov 1, 2008, 00:00

  • PCV51 SINGLE PILL AMLODIPINE/ATORVASTATIN IS COST-EFFECTIVE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA

    Nov 1, 2008, 00:00

  • PMC41 METHODOLOGICAL ISSUES IN THE LITERATURE ON COSTS OF NON-COMPLIANCE IN CHRONIC DISEASES

    Nov 1, 2008, 00:00

  • PCN55 MANAGAMENT COSTS OF PATIENTS WITH VULVAR AND VAGINAL CANCER IN FRANCE

    Nov 1, 2008, 00:00

  • PG129 INDIVIDUAL AND SOCIETAL PREFERENCE SCORES BOTH IDENTIFY ACTIVE INFLAMMATORY BOWEL DISEASE (IBD) IN GERMANY

    Nov 1, 2008, 00:00

  • PIN7 PHARMACOGENOMICS- RELEVANCE AND APPLICABILITY IN POST-GENOMIC ERA (HIV-THERAPY)

    Nov 1, 2008, 00:00

  • PHP49 ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTHTECHNOLOGY ASSESSMENT AGENCIES (HTA)

    Nov 1, 2008, 00:00

  • PG124 FURTHER VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ) IN THE SPANISH POPULATION

    Nov 1, 2008, 00:00

  • PCV96 ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE

    Nov 1, 2008, 00:00

  • PCV20 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND STATINS IN A DYSLIPIDEMIA PATIENT COHORT

    Nov 1, 2008, 00:00

  • EE6 COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK

    Nov 1, 2008, 00:00

  • PMH13 COST-UTILITY AND BUDGET IMPACT OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND

    Nov 1, 2008, 00:00

  • PRS17 COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF MODERATE AND SEVERE EXACERBATIONS OF COPD IN POLAND IN 2007

    Nov 1, 2008, 00:00

  • PIH20 WEIGHT-RELATED MORBIDITY AND FAMILY DISRUPTION FOLLOWING PEDIATRIC EMERGENCY DEPARTMENT TREATMENT (PED) OF ACUTE MINOR INJURY

    Nov 1, 2008, 00:00

  • PMS67 HEALTH GAINS FOREGONE DUETO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS- THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS

    Nov 1, 2008, 00:00

  • PCN91 TREATMENT PREFERENCE AND WILLINGNESS-TO-PAY (WTP) FOR METHYLNALTREXONE, A NOVEL PERIPHERAL OPIOID ANTAGONIST FOR OPIOID INDUCED CONSTIPATION

    Nov 1, 2008, 00:00

  • PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY- A WILLINGNESS TO PAY STUDY

    Nov 1, 2008, 00:00

  • PMS61 SHORT-TERM OUTCOMES AND HRQOL AFTER PEDIATRIC EMERGENCY DEPARTMENT (PED) TREATMENT OF MINOR INJURY- A PILOT STUDY

    Nov 1, 2008, 00:00

  • PMH44 LINGUISTIC VALIDATION, SENSITIVITY AND SPECIFICITY OF THE SCALE 'DEPRESSION IN THE MEDICALLY ILL-18'

    Nov 1, 2008, 00:00

  • PCN8 QUALITY OF LIFE-ADJUSTED SURVIVAL FOR FIRST LINE TREATMENT WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE AND VINCRISTINE (CVP) VERSUS CVP ALONE FOR PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2008, 00:00

  • PCN27 ECONOMIC EVALUATION OF A TOBACCO CESSATION PROGRAM AT A MAJOR CANCER CENTER

    Nov 1, 2008, 00:00

  • PCV37 ENOXAPARIN IS COST-SAVING AS PROPHYLACTIC THERAPY VERSUS UNFRACTIONATED HEPARIN OR NO PROPHYLAXIS IN HOSPITALISED MEDICAL PATIENTS

    Nov 1, 2008, 00:00

  • PMC62 UNIVERSAL TRANSLATION AND NEUROPSYCHOLOGICAL COMPARISONS OF PATIENTS FROM US-MEXICO BORDER REGION AND SPAIN

    Nov 1, 2008, 00:00

  • PCN84 THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM CANCER PAIN ITEM BANK (PROMIS-CA PAIN)

    Nov 1, 2008, 00:00

  • PCN80 PATIENT REPORTED QUALITY OF LIFE IN CANCER PATIENTS ON OPIOID THERAPY IS INFLUENCED BY CONSTIPATION

    Nov 1, 2008, 00:00

  • PND31 DESCRIPTIVE STUDY OF THE PHARMACOLOGICAL TREATMENTS USED IN PATIENTS WITH DEPRESSION IN PARKINSONS DISEASE (PD)

    Nov 1, 2008, 00:00

  • PSS10 SENSITIVE SKIN IN EUROPE- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS

    Nov 1, 2008, 00:00

  • PIN12 COST-EFFECTIVENESS OF CERVARIX, A PROPHYLACTIC CERVICAL CANCERVACCINE, IN SPAIN

    Nov 1, 2008, 00:00

  • PMH6 A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF BIPOLAR DISORDER IN EUROPE

    Nov 1, 2008, 00:00

  • PRS31 A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPE

    Nov 1, 2008, 00:00

  • PDB17 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2008, 00:00

  • PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

    Nov 1, 2008, 00:00

  • PCV107 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCV53 DECISION ANALYTIC MODEL FOR GENETIC TESTING IN THE MANAGEMENT OF WARFARIN ANTICOAGULATION TREATMENT FOR HOSPITALIZED PATIENTS

    Nov 1, 2008, 00:00

  • PMC57 DISCONTINUOUS COST MEASUREMENT- HOWTO FILL IN THE GAPS?

    Nov 1, 2008, 00:00

  • PCV34 COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED MAGNETIC RESONANCE (MR) ANGIOGRAPHY FOR THE PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD) IN KOREA

    Nov 1, 2008, 00:00

  • PUK7 A TEN-YEAR HORIZON COST-EFFECTIVENESS ANALYSIS OF THE SPANISH INTEGRATED RENAL REPLACEMENT THERAPY PROGRAM

    Nov 1, 2008, 00:00

  • PCN74 A SERVICE EVALUATION TO COMPARE SECONDARY CARE RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

    Nov 1, 2008, 00:00

  • PMS36 COST OF THERAPY OF TUMOR NECROSIS FACTOR BLOCKING AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY

    Nov 1, 2008, 00:00

  • PCN87 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC- PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRASTUMOR STATUS

    Nov 1, 2008, 00:00

  • EE7 ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCERVACCINATION IN ITALY- THE NATIONAL AND REGIONAL LEVEL

    Nov 1, 2008, 00:00

  • PIN34 COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY

    Nov 1, 2008, 00:00

  • PMC63 SYSTEMATIC REVIEW RELIABILITY- SENSITIVITY AND SPECIFICITY OF ONEVS.TWO REVIEWS

    Nov 1, 2008, 00:00

  • PIN46 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH VENOUS LEG ULCER

    Nov 1, 2008, 00:00

  • PCN101 RELATIONSHIP BETWEEN HEALTH CARE SUPPLY AND MAMMOGRAPHY SCREENING?

    Nov 1, 2008, 00:00

  • PHP28 A COMPARISON OF HIGH-COST HEALTH CARE PROGRAMS AVAILABLE IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PCV18 EFFECT OF ENVIRONMENTAL TEMPERATURE AND WORKDAYS ON HEART ATTACK FIGURES

    Nov 1, 2008, 00:00

  • PMS34 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PND10 BURDEN OF DISEASE IN MODERATE ALZHEIMER DISEASE PATIENTS WITH DEPRESSION IN SPAIN (IDEAL STUDY)

    Nov 1, 2008, 00:00

  • PSY64 PATIENT-REPORTED OUTCOMES (PROS) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY

    Nov 1, 2008, 00:00

  • PSY5 FACTORS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY

    Nov 1, 2008, 00:00

  • PUK3 THE COST ADVANTAGE OF INCREASING THE USE OF PERITONEAL DIALYSIS IN TURKEY

    Nov 1, 2008, 00:00

  • PMH3 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA- 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA

    Nov 1, 2008, 00:00

  • MS3 POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PRS16 THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE

    Nov 1, 2008, 00:00

  • PMH51 DECLINE IN DEPRESSION TREATMENT PERSISTS AFTER FDA ANTIDEPRESSANTWARNINGS

    Nov 1, 2008, 00:00

  • CN1 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT- BUDGET IMPACT ANALYSIS OF PACLITAXEL PROTEIN-BOUND AT A MAJOR CANCER CENTER

    Nov 1, 2008, 00:00

  • PMS32 THE DIRECT HEALTH CARE COSTS OF OSTEOARTHRITIS- EVIDENCE FROM US NATIONAL SURVEY DATA

    Nov 1, 2008, 00:00

  • PCV78 ANEURYSM OCCLUSION IN ELDERLY PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE- A COST-UTILITY ANALYSIS

    Nov 1, 2008, 00:00

  • PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION-A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND

    Nov 1, 2008, 00:00

  • PRS5 ESTABLISHING THE INCIDENCE AND PREVALENCE OF MULTIPLE A TOPIC CONDITIONS IN UK- COHORT STUDY USING THE GENERAL PRACTICE RESEARCH DATABASE

    Nov 1, 2008, 00:00

  • PSY30 HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY- IS INITIAL DOSING A SIGNIFICANT FACTOR?

    Nov 1, 2008, 00:00

  • PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

    Nov 1, 2008, 00:00

  • PSS37 IDENTIFYING NON COMPLIANT GLAUCOMA PATIENTS USING THE EDSQ, A QUESTIONNAIRE MEASURING SATISFACTION AND COMPLIANCE OF GLAUCOMA TREATMENT

    Nov 1, 2008, 00:00

  • PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?

    Nov 1, 2008, 00:00

  • PUK5 COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS

    Nov 1, 2008, 00:00

  • PCV44 COST-EFFECTIVENESS MODEL OF IMPLANTABLE CARDIAC MONITORS (ICM) FOR PATIENTS TREATED WITH RADIOFREQUENCY CATHETER ABLATION FOR A TRIAL FIBRILLATION (PAAF) IN SPAIN

    Nov 1, 2008, 00:00

  • PCN23 COST EFFECTIVENESS OF CLODRONATE AND ZOLENDRONATE FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BRAZIL- PUBLIC HEALTH PERSPECTIVE

    Nov 1, 2008, 00:00

  • QL5 COMPARISON OF EQ-5D AND HUI3 IN PATIENTS WITH TINNITUS

    Nov 1, 2008, 00:00

  • PMS2 DIAGNOSIS OF OSTEOPOROSIS BY DUAL X-RAY AND LASER (DXL) DENSITOMETRY-A HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PMH17 TREATMENT OF OPIATE DEPENDENT PATIENTS INWALES WITH BUPRENORPHINE/NALOXONE-A COST-EFFECTIVENESS EVALUATION

    Nov 1, 2008, 00:00

  • PCV57 ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED BY TREATING TO ALTERNATIVE LDL-C TARGETS- IS LOWER BETTER?

    Nov 1, 2008, 00:00

  • QL11 FATIGUE REDUCTION AND PHYSICAL FUNCTION IMPROVEMENTS ASSOCIATED WITH INCREASED PRODUCTIVITY AT WORK AND AT HOME IN RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2008, 00:00

  • PCV9 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF IRBESARTANVS. CANDESARTAN

    Nov 1, 2008, 00:00

  • PMC40 STABILITY OF TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) STRUCTURE IN DIFFERENT PATHOLOGY SAMPLES

    Nov 1, 2008, 00:00

  • PND25 EVALUATION OF A BRIEF DEMENTIA SCREENING TEST FOR PARKINSONS DISEASE (PD-BDST) IN A CLINICAL PRACTICE SETTING

    Nov 1, 2008, 00:00

  • QL7 INTERPRETING SCORES ON THREE COPD PATIENT-REPORTED OUTCOME MEASURES

    Nov 1, 2008, 00:00

  • PCV27 MODELING THE FISCAL IMPACT OF USING PERFLUTREN LIPID MICROSPHERES (PLM) FOR FOLLOW-UP ECHOCARDIOGRAPHIC IMAGING

    Nov 1, 2008, 00:00

  • PG128 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A NEW QUESTIONNAIRE MEASURING THE IMPACT OF CHILD GASTROENTERITIS ON PARENTS

    Nov 1, 2008, 00:00

  • PMS45 OUTPATIENT MEDICAL MANAGEMENT OF FIBROMYALGIA IN FRANCE COMPARED TO THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))

    Nov 1, 2008, 00:00

  • PCV43 MODELED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE LIPID TARGETSWHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH SIMVASTATIN, ROSUVASTATIN, AND ATORVASTATIN

    Nov 1, 2008, 00:00

  • PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8 IN COMPARISON TO NPH AND PREMIX IN POLAND?

    Nov 1, 2008, 00:00

  • PG131 GENDER, AGE AND BODY MASS-RELATED DIFFERENCES IN THE IMPACT OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOMS IN PRIMARY CARE PATIENTS ASSESSED BY THE GASTROINTESTINAL IMPACT SCALE (GIS)

    Nov 1, 2008, 00:00

  • PSS7 A MIXED TREATMENT COMPARISON OF TOPICAL OCULAR HYPOTENSIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

    Nov 1, 2008, 00:00

  • PMS1 COGNITIVE IMPAIRMENT IN PATIENTS WITH FIBROMYALGIA SYNDROME AS ASSESSED BY THE MINIMENTAL STATE EXAMINATION

    Nov 1, 2008, 00:00

  • PIN47 VALIDATION OF THE SINONASAL OUTCOMETEST-16 (SNOT-16) IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2008, 00:00

  • MH6 ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS- RESULTS FROM THE COMETA STUDY

    Nov 1, 2008, 00:00

  • PCV12 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF ARBS VS. ACE INHIBITORS

    Nov 1, 2008, 00:00

  • PDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE SECTOR IN SOUTH AFRICA

    Nov 1, 2008, 00:00

  • PSY2 CONTRIBUTIONS OF THE FABRY OUTCOME SURVEY (FOS) TO ADVANCING THE MANAGEMENT OF FABRY DISEASE

    Nov 1, 2008, 00:00

  • PDB60 A COMPARISON OF THE MANAGEMENT OF SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES- SIMILARITIES, DIFFERENCES AND RESOURCE IMPLICATIONS

    Nov 1, 2008, 00:00

  • PCV120 GLYCOPROTEIN INHIBITOR USE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)

    Nov 1, 2008, 00:00

  • PSS16 SENSITIVE SKINS IN GERMANY- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PSY12 COST-EFFECTIVENESS OF FOOD FOR SPECIAL MEDICAL PURPOSES RELATIVE TO STANDARD CARE IN PATIENTS UNDERGOING ABDOMINAL SURGERY

    Nov 1, 2008, 00:00

  • PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSIS-RELATED HIP FRACTURES

    Nov 1, 2008, 00:00

  • PSS38 RELATION BETWEEN SELF REPORTED GLAUCOMA SYMPTOMS AND COMPLIANCE

    Nov 1, 2008, 00:00

  • PCV89 THE COST EFFECTIVENESS OF PERSISTENCE TO ANTIHYPERTENSIVE TREATMENT

    Nov 1, 2008, 00:00

  • PCV122 MODELING THE EFFECT OF DIFFERENTIAL COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS ON CLINICAL ENDPOINTS

    Nov 1, 2008, 00:00

  • PMS3 A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE VS OTHER THERAPUETIC OPTIONS IN THE TREATEMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PSY32 COSTS OF A BLOODTRANSFUSION IN HEMATO-ONCOLOGIC PATIENTS IN A PORTUGUESE HOSPITAL

    Nov 1, 2008, 00:00

  • PND12 COSTS OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PSY62 A NATURAL EXPERIMENT TO ESTIMATE THE IMPACT OF A PREFERRED DRUG LIST POLICY FOR LONG ACTING NARCOTIC ANALGESICS ON COSTS AND UTILIZATION

    Nov 1, 2008, 00:00

  • PSY21 COST-MINIMIZATION ANALYSIS OF ORALVS. INTRAVENOUS FLUDARABINE (BENEFLUR) IN SPAIN

    Nov 1, 2008, 00:00

  • PCN85 PATIENT PREFERENCES IN THE THERAPY OF MULTIPLE MYELOMA

    Nov 1, 2008, 00:00

  • PHP6 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 483 IN SPAIN- A POPULATION-BASED STUDY

    Nov 1, 2008, 00:00

  • PCV65 COSTS OF BLEEDS ASSOCIATED WITH TREATING ACUTE CORONARY SYNDROME PATIENTS IN GERMANY

    Nov 1, 2008, 00:00

  • PCV94 PREDICTORS OF HEALTH STATUS CHANGE AMONG PATIENTS TREATED WITH A CALCIUM ANTAGONISTOR AN ATENOLOL-LED HYPERTENSION STRATEGY IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)

    Nov 1, 2008, 00:00

  • PMS13 IMPACT OFVIOXX WITHDRAWAL ON VOLUME OF TOTAL HIP AND KNEE REPLACEMENTS

    Nov 1, 2008, 00:00

  • PRS3 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ADMINISTRATIVE HEATH SERVICES DATABASES

    Nov 1, 2008, 00:00

  • PIH24 ASSESSMENT OF CURRENT CLINICAL PRACTICE AMONG PHYSICIANS AND SEX THERAPISTS REGARDING ERECTILE DYSFUNCTION (ED) TREATMENT INITIATION WITH PHOSPHODIESTERASE-5 INHIBITORS (PDE5I)

    Nov 1, 2008, 00:00

  • PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER

    Nov 1, 2008, 00:00

  • QL6 ROLE OF DISEASE SPECIFIC INSTRUMENTS IN THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CANCER CLINICAL TRIALS

    Nov 1, 2008, 00:00

  • PRS25 THE PUBLICS WILLINGNESS TO PAY FOR A QALY IN THAILAND

    Nov 1, 2008, 00:00

  • PIN52 UTILIZATION ANALYSIS AND IMPACT OF ANTIBACTERIAL AGENTS IN TWO LEADING UNIVERSITY HOSPITALS IN NEIGHBORING COUNTRIES WITH DIFFERENT GDP AND HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PCV24 BUDGET IMPACT OF GUIDELINE ADHERENT THERAPY IN ACUTE CORONARY SYNDROME (ACS) IN GERMANY

    Nov 1, 2008, 00:00

  • PSY42 E-DIARY COMPLIANCE IN ACUTE PAIN STUDIES

    Nov 1, 2008, 00:00

  • PHP22 COMPARATIVE ANALYSIS OF HOSPITAL BED CAPACITITES OF OLD (EU-15) AND NEW (EU-12) MEMBERSTATES OF THE EUROPEAN UNION

    Nov 1, 2008, 00:00

  • PCV59 INPATIENT RESOURCE USE ASSOCIATED WITHTHE TREATMENT OF SECONDARY A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PCV2 UNDERUSE OF STATINES AMONG HIGH RISK PATIENTS

    Nov 1, 2008, 00:00

  • PUK18 VALIDATION OF THE URINARY SENSATION SCALE (USS)

    Nov 1, 2008, 00:00

  • PG13 PHARMACOECONOMIC ASSESSMENT OF LANREOTIDE IN THE MANAGEMENT OF POST-OPERATIVE DIGESTIVE FISTULAS

    Nov 1, 2008, 00:00

  • PCN44 COST MINIMIZATION ANALYSIS OF ADVANCED GASTRIC CANCERTREATMENT WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN POLISH SETTING

    Nov 1, 2008, 00:00

  • PCN102 THE BURDEN OF RENAL CELL CANCER- A RETROSPECTIVE LONGITUDINAL STUDY ON OCCURRENCE, OUTCOMES AND COST USING AN ADMINISTRATIVE CLAIMS DATABASE

    Nov 1, 2008, 00:00

  • Disclosure Information

    Nov 1, 2008, 00:00

  • PMS35 RHEUMATOID ARTHRITIS COST STUDY RESULTS IN POLAND

    Nov 1, 2008, 00:00

  • PND21 SYMPTOM SEVERITY IN PARKINSONS DISEASE SEVERITY

    Nov 1, 2008, 00:00

  • PDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA- A LONGTERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY

    Nov 1, 2008, 00:00

  • PRS41 USE OF AN ELECTRONIC DIARY IN 55 COUNTIRES- WHAT ARE THE CHALLENGES?

    Nov 1, 2008, 00:00

  • PG19 THE COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS ESOMEPRAZOLE IN PEPTIC ULCER BLEEDING- A DECISION-TREE MODEL WITH SPANISH COSTS AND NEW CLINICAL DATA

    Nov 1, 2008, 00:00

  • PSY44 UNDERSTANDING AND ASSESSING THE IMPACT OF PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL, GENDER AND CULTURAL ISSUES

    Nov 1, 2008, 00:00

  • PHP44 IN EQUALITIES IN THE FINANCING OF DRUGS AMONG AUTONOMOUS REGIONS IN SPAIN

    Nov 1, 2008, 00:00

  • PCV97 TREATMENTS FOR VARICOSE VEIN DISEASE- EXPECTATIONS AND EXPERIENCES OF PATIENTS

    Nov 1, 2008, 00:00

  • MD4 UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY- COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY

    Nov 1, 2008, 00:00

  • PIN5 IMPACT OF MASS VACCINATION WITH MMRV VERSUS MMR IN FRANCE ON THE EPIDEMIOLOGY OF VARICELLA AND HERPES ZOSTER, USING A DYNAMIC TRANSMISSION MODEL

    Nov 1, 2008, 00:00

  • PCN7 ANALYSIS AND CATEGORISATION OF DRUG-RELATED PROBLEMS ASSOCIATED WITH SYSTEMIC BREAST CANCER THERAPY

    Nov 1, 2008, 00:00

  • PRS26 THE EXACT-PRO INITIATIVE- DEVELOPMENT AND VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME MEASURE FOR EVALUATING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2008, 00:00

  • PG136 SELF-DIAGNOSIS AND HEALTH SEEKING BEHAVIOUR OF WOMEN FOR MINOR BOWL AILMENTS IN A LARGE REPRESENTATIVE UNITED KINGDOM (UK) SAMPLE POPULATION

    Nov 1, 2008, 00:00

  • PDB33 COST COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN TYPE 2 DIABETES MELLITUS IN ARGENTINA- A TRIAL-BASED PROBABILISTIC MODEL

    Nov 1, 2008, 00:00

  • PSS35 COST UTILITY OF BILATERAL COCHLEAR IMPLANT

    Nov 1, 2008, 00:00

  • PUK8 FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER- RESULTS OF AN ECONOMIC MODEL

    Nov 1, 2008, 00:00

  • PUK2 IN GREECE, INCREASING THE UTILIZATION OF PERITONEAL DIALYSIS THERAPY MAY REDUCE OVERALL DIALYSIS EXPENDITURES

    Nov 1, 2008, 00:00

  • PG137 A COMPARISON OF TREATMENT FAILURE RATES BASED ON STARTING ALGINATE THERAPY OBSERVED IN A LARGE REPRESENTATIVE LONGITUDINAL UK DATABASE

    Nov 1, 2008, 00:00

  • PUK19 PSYCHOMETRIC EVALUATION OF THE KHQ IN TEN LANGUAGES

    Nov 1, 2008, 00:00

  • QL2 TRANSLATION OF THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) FOR USE IN 33 COUNTRIES

    Nov 1, 2008, 00:00

  • PCN59 ECONOMIC BURDEN OF TREATING VIN AND VAIN 2/3 IN GERMANY

    Nov 1, 2008, 00:00

  • PCN100 CONSUMPTION AND ACCESS TO INNOVATIVE CANCER DRUGS IN SLOVAKIA

    Nov 1, 2008, 00:00

  • PSY17 PRECISE STUDY- BASELINE ANALYSIS OF A COST EFFECTIVENESS STUDY ON FAILED BACK SURGERY SYNDROME

    Nov 1, 2008, 00:00

  • PMS44 PARAMEDICAL OR ALTERNATIVE TREATMENTS AND ASSOCIATED COSTS FOR THE MANAGEMENT OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PG117 REALWORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHNS DISEASE

    Nov 1, 2008, 00:00

  • PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

    Nov 1, 2008, 00:00

  • PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC

    Nov 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155 (current)
  • 156
  • 157
  • 158
  • 159
  • 160
  • »